RxDoctor Payments Data

Maryam Amini, MD

Family Medicine · Walnut Creek, CANPI 1245402072

Payments from drug & device makers

$2,134in general payments, 2019–2025

Across 81 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$348
  • AstraZeneca$233
  • Novo Nordisk$229
  • Actelion Pharmaceuticals US, Inc.$182
  • Bayer$123
  • Medtronic$105
  • plus $914 from 23 others

What the payments were for

  • Food & beverage$2,134100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,134 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$281,548
Medicare patients
134
Services billed
3,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$41,685
JanuviaSitagliptin Phosphate18$18,985
MounjaroTirzepatide11$10,579
Atorvastatin Calcium185$2,156
Levothyroxine Sodium147$1,664
Metoprolol Succinate109$1,607
Amlodipine Besylate172$1,082
Gabapentin46$993
Metformin Hcl93$908
Rosuvastatin Calcium44$900
Memantine Hcl17$836
Labetalol Hcl14$619
Lisinopril86$567
Losartan Potassium41$530
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$41,68535 claims
MerckJanuvia$41$18,98518 claims
Lilly USA, LLCMounjaro$50$10,57911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →